132 related articles for article (PubMed ID: 18840469)
21. Yield increases in intact influenza vaccine virus from chicken allantoic fluid through isolation from insoluble allantoic debris.
Hughes K; Zachertowska A; Wan S; Li L; Klimaszewski D; Euloth M; Hatchette TF
Vaccine; 2007 May; 25(22):4456-63. PubMed ID: 17418461
[TBL] [Abstract][Full Text] [Related]
22. HPLC-based quantification of haemagglutinin in the production of egg- and MDCK cell-derived influenza virus seasonal and pandemic vaccines.
Kapteyn JC; Porre AM; de Rond EJ; Hessels WB; Tijms MA; Kessen H; Slotboom AM; Oerlemans MA; Smit D; van der Linden J; Schoen P; Thus JL
Vaccine; 2009 Feb; 27(9):1468-77. PubMed ID: 19110022
[TBL] [Abstract][Full Text] [Related]
23. Downstream processing of MDCK cell-derived equine influenza virus.
Nayak DP; Lehmann S; Reichl U
J Chromatogr B Analyt Technol Biomed Life Sci; 2005 Sep; 823(2):75-81. PubMed ID: 16009601
[TBL] [Abstract][Full Text] [Related]
24. A flow-through chromatography process for influenza A and B virus purification.
Weigel T; Solomaier T; Peuker A; Pathapati T; Wolff MW; Reichl U
J Virol Methods; 2014 Oct; 207():45-53. PubMed ID: 24992667
[TBL] [Abstract][Full Text] [Related]
25. The growth of attenuated influenza vaccine donor strains in continuous cell lines.
Audsley JM; Tannock GA
J Virol Methods; 2005 Feb; 123(2):187-93. PubMed ID: 15620401
[TBL] [Abstract][Full Text] [Related]
26. Monitoring of influenza virus hemagglutinin in process samples using weak affinity ligands and surface plasmon resonance.
Mandenius CF; Wang R; Aldén A; Bergström G; Thébault S; Lutsch C; Ohlson S
Anal Chim Acta; 2008 Aug; 623(1):66-75. PubMed ID: 18611459
[TBL] [Abstract][Full Text] [Related]
27. Isolation of influenzavirus A and B in PLC/PRF/5 cells.
Bryden AS
Br J Biomed Sci; 1996 Jun; 53(2):93-5. PubMed ID: 8757684
[TBL] [Abstract][Full Text] [Related]
28. Structural and evolutionary characteristics of HA, NA, NS and M genes of clinical influenza A/H3N2 viruses passaged in human and canine cells.
Zhirnov OP; Vorobjeva IV; Saphonova OA; Poyarkov SV; Ovcharenko AV; Anhlan D; Malyshev NA
J Clin Virol; 2009 Aug; 45(4):322-33. PubMed ID: 19546028
[TBL] [Abstract][Full Text] [Related]
29. Development and strategies of cell-culture technology for influenza vaccine.
Feng SZ; Jiao PR; Qi WB; Fan HY; Liao M
Appl Microbiol Biotechnol; 2011 Feb; 89(4):893-902. PubMed ID: 21063703
[TBL] [Abstract][Full Text] [Related]
30. An adenovirus vector-mediated reverse genetics system for influenza A virus generation.
Ozawa M; Goto H; Horimoto T; Kawaoka Y
J Virol; 2007 Sep; 81(17):9556-9. PubMed ID: 17596315
[TBL] [Abstract][Full Text] [Related]
31. [Analysis of influenza surveillance from 2000 to 2007 in Gansu province].
Li HY; Yu DS; Chen JH; Liu XZ
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2008 Aug; 22(4):266-8. PubMed ID: 19105339
[TBL] [Abstract][Full Text] [Related]
32. Infection dynamics and virus-induced apoptosis in cell culture-based influenza vaccine production-Flow cytometry and mathematical modeling.
Schulze-Horsel J; Schulze M; Agalaridis G; Genzel Y; Reichl U
Vaccine; 2009 May; 27(20):2712-22. PubMed ID: 19428884
[TBL] [Abstract][Full Text] [Related]
33. Phenotypic and genetic analyses of the heterogeneous population present in the cold-adapted master donor strain: A/Leningrad/134/17/57 (H2N2).
Youil R; Kiseleva I; Kwan WS; Szymkowiak C; Toner TJ; Su Q; Klimov A; Rudenko L; Shaw AR
Virus Res; 2004 Jun; 102(2):165-76. PubMed ID: 15084398
[TBL] [Abstract][Full Text] [Related]
34. Trivalent MDCK cell culture-derived influenza vaccine Optaflu (Novartis Vaccines).
Doroshenko A; Halperin SA
Expert Rev Vaccines; 2009 Jun; 8(6):679-88. PubMed ID: 19485748
[TBL] [Abstract][Full Text] [Related]
35. Downstream processing of Vero cell-derived human influenza A virus (H1N1) grown in serum-free medium.
He C; Yang Z; Tong K
J Chromatogr A; 2011 Aug; 1218(31):5279-85. PubMed ID: 21726872
[TBL] [Abstract][Full Text] [Related]
36. Development of a live-attenuated influenza B DeltaNS1 intranasal vaccine candidate.
Wressnigg N; Voss D; Wolff T; Romanova J; Ruthsatz T; Mayerhofer I; Reiter M; Nakowitsch S; Humer J; Morokutti A; Muster T; Egorov A; Kittel C
Vaccine; 2009 May; 27(21):2851-7. PubMed ID: 19366569
[TBL] [Abstract][Full Text] [Related]
37. N-glycan analysis by CGE-LIF: profiling influenza A virus hemagglutinin N-glycosylation during vaccine production.
Schwarzer J; Rapp E; Reichl U
Electrophoresis; 2008 Nov; 29(20):4203-14. PubMed ID: 18925582
[TBL] [Abstract][Full Text] [Related]
38. Comparative analysis of reproduction of influenza virus strains in cell lines perspective for the creation of cultural vaccines grown on nutrient medium on the basis of rise flour protein hydrolysate.
Mazurkova NA; Troshkova GP; Sumkina TP; Kolokol'tsova TD; Skarnovich MO; Kabanov AS; Shishkina LN; Sergeev AN
Bull Exp Biol Med; 2008 Oct; 146(4):547-50. PubMed ID: 19489339
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of chicken-origin (DF-1) and quail-origin (QT-6) fibroblast cell lines for replication of avian influenza viruses.
Lee CW; Jung K; Jadhao SJ; Suarez DL
J Virol Methods; 2008 Oct; 153(1):22-8. PubMed ID: 18638503
[TBL] [Abstract][Full Text] [Related]
40. Scalable production of influenza virus in HEK-293 cells for efficient vaccine manufacturing.
Le Ru A; Jacob D; Transfiguracion J; Ansorge S; Henry O; Kamen AA
Vaccine; 2010 May; 28(21):3661-71. PubMed ID: 20347632
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
